Dimensional Fund Advisors LP Boosts Position in Janux Therapeutics, Inc. (NASDAQ:JANX)

Dimensional Fund Advisors LP boosted its holdings in shares of Janux Therapeutics, Inc. (NASDAQ:JANX) by 54.0% in the second quarter, HoldingsChannel.com reports. The institutional investor owned 24,019 shares of the company’s stock after purchasing an additional 8,422 shares during the quarter. Dimensional Fund Advisors LP’s holdings in Janux Therapeutics were worth $1,005,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently bought and sold shares of JANX. Lord Abbett & CO. LLC purchased a new position in Janux Therapeutics during the 1st quarter worth approximately $20,420,000. Vanguard Group Inc. raised its position in Janux Therapeutics by 38.6% during the 1st quarter. Vanguard Group Inc. now owns 1,357,960 shares of the company’s stock worth $51,127,000 after buying an additional 378,477 shares during the last quarter. Altitude Crest Partners Inc. purchased a new position in Janux Therapeutics during the 1st quarter worth approximately $7,278,000. StemPoint Capital LP purchased a new position in Janux Therapeutics during the 1st quarter worth approximately $4,580,000. Finally, Bank of New York Mellon Corp raised its position in Janux Therapeutics by 136.3% during the 2nd quarter. Bank of New York Mellon Corp now owns 115,027 shares of the company’s stock worth $4,818,000 after buying an additional 66,340 shares during the last quarter. 75.39% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Janux Therapeutics news, insider Andrew Hollman Meyer sold 50,000 shares of Janux Therapeutics stock in a transaction on Friday, September 27th. The shares were sold at an average price of $45.96, for a total transaction of $2,298,000.00. Following the sale, the insider now owns 67,592 shares of the company’s stock, valued at $3,106,528.32. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In other Janux Therapeutics news, major shareholder Ventures Xi L.P. Avalon sold 108,365 shares of Janux Therapeutics stock in a transaction on Friday, September 6th. The shares were sold at an average price of $42.00, for a total transaction of $4,551,330.00. Following the sale, the insider now owns 3,162,851 shares of the company’s stock, valued at $132,839,742. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Andrew Hollman Meyer sold 50,000 shares of Janux Therapeutics stock in a transaction on Friday, September 27th. The stock was sold at an average price of $45.96, for a total transaction of $2,298,000.00. Following the sale, the insider now directly owns 67,592 shares in the company, valued at approximately $3,106,528.32. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 393,767 shares of company stock valued at $17,857,979. 35.40% of the stock is owned by corporate insiders.

Janux Therapeutics Stock Performance

Shares of NASDAQ JANX opened at $49.55 on Friday. The firm has a market cap of $2.57 billion, a PE ratio of -40.61 and a beta of 3.54. The firm has a fifty day moving average of $44.42 and a 200 day moving average of $45.01. Janux Therapeutics, Inc. has a one year low of $5.65 and a one year high of $65.60.

Janux Therapeutics (NASDAQ:JANX) last issued its quarterly earnings results on Wednesday, August 7th. The company reported ($0.11) EPS for the quarter, topping the consensus estimate of ($0.31) by $0.20. The company had revenue of $8.90 million during the quarter, compared to analyst estimates of $0.77 million. Janux Therapeutics had a negative net margin of 291.17% and a negative return on equity of 8.78%. The company’s revenue was up 709.1% on a year-over-year basis. On average, equities analysts predict that Janux Therapeutics, Inc. will post -1.18 EPS for the current fiscal year.

Analysts Set New Price Targets

JANX has been the subject of several recent research reports. HC Wainwright reaffirmed a “buy” rating and set a $63.00 target price on shares of Janux Therapeutics in a report on Monday, August 19th. Stifel Nicolaus initiated coverage on shares of Janux Therapeutics in a report on Friday, September 6th. They set a “buy” rating and a $70.00 target price for the company. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $100.00 target price on shares of Janux Therapeutics in a report on Monday, September 16th. Wedbush reaffirmed an “outperform” rating and set a $74.00 target price on shares of Janux Therapeutics in a report on Thursday, August 8th. Finally, Scotiabank cut their target price on shares of Janux Therapeutics from $47.00 to $42.00 and set a “sector perform” rating for the company in a report on Friday, August 9th. One investment analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. According to MarketBeat, Janux Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $66.13.

Janux Therapeutics Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.